Dr Reddy's Laboratories Ltd founder-chairman Kallam Anji Reddy spoke in an interview about the evolution of the pharmaceutical industry and emerging trends as well drug discovery research and generic medicine. Edited excerpts: On evolution of the Indian pharma industry To start with, pharma was an industry based on innovation, drug discovery. When Big Pharma discovered drugs way back--I am talking about 25 years back--when someone started to make generics, they first said how you can equate a copycat to us, even though the patent has expired. When the government insisted that you have to have a criterion by which you can call it equal, then Big Pharma itself said there is what is called bio- equivalence.
If you establish the bio- equivalence of a generic drug, then you can allow them. One company, for example, several years ago made a bioequivalent version of a Pfizer drug, and then when the bio-equivalence was as good as or even better than Pfizer's, then they said it's not bio-equivalence alone.
Those were the days when I was actually doing my PhD in NCL (National Chemical Laboratory, Pune)--I am talking about 1965-66--so 35 years ago. There was a stinging editorial in an American pharmaceutical journal--what do you mean by not bio-equivalence alone; is it something special or is it something which cannot be scientifically proved? So they (Big Pharma) had no arguments.
